查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1620685

血漿分餾市場：按產品、應用和最終用戶分類 - 全球預測 2025-2030 年

Plasma Fractionation Market by Product (Albumin, Coagulation Factor Concentrates, Immunoglobulin), Application (Critical Care, Hemato-Oncology, Hematology), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年血漿分餾市場價值為355.2億美元，預計到2024年將達到389.5億美元，複合年成長率為10.45%，到2030年將達到712.7億美元。

血漿分餾是指分離精製血漿成分的過程，主要用於醫療。這包括免疫球蛋白、白蛋白和凝血因子等蛋白質，它們對於治療免疫力缺乏、血友病、自體免疫疾病等多種治療應用至關重要。對血漿分餾的需求源於對血漿衍生療法的迫切需求，以治療無法用合成替代品有效治療的慢性疾病。因此，它的主要用途是作為需要長期治療的疾病的藥物。最終用途領域主要是醫院、研究機構和製藥公司。市場受到個人化醫療需求不斷成長、醫療基礎設施進步以及血漿治療意識不斷增強的顯著影響。改進的血漿分離純化工藝和人工智慧在診斷中的整合等技術進步帶來了潛在的成長機會。抓住這些機會的主要建議包括投資研發以提高產品效率以及形成策略聯盟以簡化供應鏈流程。然而，血漿治療的高成本、血漿捐獻的倫理問題以及一些地區嚴格的監管要求都是限制因素。此外，由於捐贈者的可用性而導致的血漿供應波動可能會為滿足全球需求帶來挑戰。尋求成長的公司應專注於加強捐助者招募策略和開發可以緩解供應問題的合成或替代蛋白質等領域。創新還可以針對改進分餾技術，以提高產量比率和安全標準。鑑於市場的競爭格局，對監管格局的透徹了解和對技術升級的持續投資對於持續成功至關重要。此外，關注教育和宣傳宣傳活動可以減輕對捐贈的擔憂，並最終支持市場擴張。

主要市場統計
基準年[2023] 355.2億美元
預計年份 [2024] 389.5億美元
預測年份 [2030] 712.7億美元
複合年成長率（%） 10.45%

市場動態：揭示快速發展的血漿分餾市場的關鍵市場見解

供需的動態交互作用正在改變血漿分餾市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 改善血漿療法的可及性以及免疫球蛋白在各個治療領域的高利用率
    • 政府努力增加血漿採集
    • 世界老年人口增加及採血設施增加
  • 市場限制因素
    • 存在對目前病毒去活化治療具有抗藥性的新病原體
  • 市場機會
    • 製程開發技術的不斷進步以改進配方
    • 新臨床試驗的使用迅速增加，活性化血漿療法的研發活動
  • 市場問題
    • 關於血漿分餾和替代重組療法的存在的嚴格政府法規

波特五力：駕馭血漿分餾市場的策略工具

波特的五力架構是了解血漿分餾市場競爭格局的關鍵工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解血漿分餾市場的外部影響

外部宏觀環境因素在塑造血漿分餾市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解血漿分餾市場的競爭格局

血漿分餾市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：血漿分餾市場供應商的績效評估

FPNV定位矩陣是評估血漿分餾市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製血漿分餾市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，血漿分餾市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開發：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 改善血漿治療的可及性並在各個治療領域大量使用免疫球蛋白
      • 政府努力增加血漿採集
      • 隨著世界各地老年人數量的增加，採血設施的數量也增加。
    • 抑制因素
      • 存在對目前病毒去活化治療具有抗藥性的新病原體
    • 機會
      • 製程開發技術的不斷進步以改進配方
      • 在新的臨床試驗中廣泛應用，並擴大血漿治療的研發活動
    • 任務
      • 關於血漿分餾和替代重組療法的存在的嚴格政府法規
  • 市場區隔分析
    • 產品：增加血漿分餾在免疫球蛋白精製的使用
    • 應用：擴大用於治療血液疾病
    • 最終用戶：血漿分餾廣泛用於臨床實驗室，以確保血漿衍生產品的安全性和有效性。
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章血漿分餾市場：依產品

  • 介紹
  • 白蛋白
  • 濃縮凝血因子
    • 因子IX
    • 因子VIII
    • 因子XIII
    • 纖維蛋白原濃縮物
    • 凝血酶原複合物濃縮物
    • 血管性血友病因子
  • 免疫球蛋白
    • 靜脈注射免疫球蛋白
    • 皮下注射免疫球蛋白
  • 蛋白酶抑制劑

第7章血漿分餾市場：依應用分類

  • 介紹
  • 加護治療
  • 血液腫瘤學
  • 血液學
  • 神經病學
  • 呼吸系統醫療設備
  • 風濕病學

第8章血漿分餾市場：依最終用戶分類

  • 介紹
  • 學術研究所
  • 臨床研究實驗室

第9章美洲血漿分餾市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太血漿分餾市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲/中東/非洲血漿分餾市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Grifols 埃及運送第一批由埃及捐贈血漿製成的血漿藥物
    • CSL 耗資 4.7 億美元的血漿分餾設施在德國馬爾堡開業
    • 武田將投資 1,000 億日圓在日本新血漿分餾產品生產設施
    • Kedrion 在沙烏地阿拉伯的血漿分餾研討會上發表演講
  • 戰略分析和建議

公司名單

  • 3M Company
  • ADMA Biologics, Inc.
  • Bharat Serums and Vaccines Limited
  • Bio Products Laboratory Ltd.
  • BIoTest AG by Grifols, SA
  • China Biologic Products, Inc.
  • CSL Limited
  • Emergent BioSolutions Inc.
  • Fusion Health Care Pvt. Ltd.
  • GC Biopharma corp.
  • Grifols, SA
  • HEINKEL Process Technology GmbH
  • Hemarus Therapeutics Ltd
  • Intas Pharmaceuticals Ltd.
  • Kamada Ltd.
  • Kedrion SpA
  • LFB SA
  • Merck KGaA
  • Octapharma AG
  • PlasmaGen BioSciences Pvt. Ltd.
  • Prothya Biosolutions BV
  • Sanquin
  • Shanghai Raas Blood Products Co. Ltd
  • SK Plasma Co.,Ltd.
  • STERIS plc
  • Takeda Pharmaceutical Company Ltd
Product Code: MRR-4312A385A58A

The Plasma Fractionation Market was valued at USD 35.52 billion in 2023, expected to reach USD 38.95 billion in 2024, and is projected to grow at a CAGR of 10.45%, to USD 71.27 billion by 2030.

Plasma fractionation refers to the process of separating and purifying components of plasma, primarily used in medical therapies. This includes proteins such as immunoglobulins, albumin, and clotting factors that are essential for various therapeutic applications in treating conditions like immune deficiencies, hemophilia, and autoimmune disorders. The necessity of plasma fractionation arises from the critical need for plasma-derived therapies to manage chronic ailments that cannot otherwise be treated effectively with synthetic alternatives. As such, the primary application involves medicinal use, especially for diseases requiring long-term treatment. End-use sectors mainly include hospitals, research institutions, and pharmaceutical companies. The market is significantly influenced by increasing demand for personalized medicine, advancements in healthcare infrastructure, and rising awareness about plasma therapies. Technological advancements like improved plasma purification processes and integration of artificial intelligence in diagnostics present potential opportunities for growth. Key recommendations to seize these opportunities include investing in R&D to enhance product efficacy and forming strategic alliances to streamline supply chain processes. However, the market is constrained by factors such as the high cost of plasma therapies, ethical concerns regarding plasma donation, and stringent regulatory requirements across different regions. Moreover, fluctuations in plasma supply due to donors' availability can pose challenges in meeting global demand. Companies seeking growth should focus on areas like enhancing donor recruitment strategies and developing synthetic or alternative protein substitutes that could alleviate supply issues. Innovation could also be directed towards improving fractionation technologies to boost yield and safety standards. Given the competitive nature of the market, a thorough understanding of regulatory landscapes, and continuous investment in technological upgrades are essential for sustained success. Emphasis on education and awareness campaigns can also help mitigate donation concerns, ultimately supporting market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 35.52 billion
Estimated Year [2024] USD 38.95 billion
Forecast Year [2030] USD 71.27 billion
CAGR (%) 10.45%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Plasma Fractionation Market

The Plasma Fractionation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Improving access to plasma-based therapies and high use of immunoglobulins in various therapeutic areas
    • Government initiatives to increase plasma collection
    • Growing prevalence of elderly people around the globe and the increasing number of blood collection facilities
  • Market Restraints
    • Presence of new pathogenic agents that resist the present viral inactivation treatments
  • Market Opportunities
    • Continuous advancements in process development technology for improved formulations
    • Exponential utilization in new clinical trials and growing R&D activities in plasma treatment
  • Market Challenges
    • Stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies

Porter's Five Forces: A Strategic Tool for Navigating the Plasma Fractionation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Plasma Fractionation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Plasma Fractionation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Plasma Fractionation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Plasma Fractionation Market

A detailed market share analysis in the Plasma Fractionation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Plasma Fractionation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Plasma Fractionation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Plasma Fractionation Market

A strategic analysis of the Plasma Fractionation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Plasma Fractionation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, ADMA Biologics, Inc., Bharat Serums and Vaccines Limited, Bio Products Laboratory Ltd., Biotest AG by Grifols, S.A., China Biologic Products, Inc., CSL Limited, Emergent BioSolutions Inc., Fusion Health Care Pvt. Ltd., GC Biopharma corp., Grifols, S.A., HEINKEL Process Technology GmbH, Hemarus Therapeutics Ltd, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A., LFB SA, Merck KGaA, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions B.V., Sanquin, Shanghai Raas Blood Products Co. Ltd, SK Plasma Co.,Ltd., STERIS plc, and Takeda Pharmaceutical Company Ltd.

Market Segmentation & Coverage

This research report categorizes the Plasma Fractionation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Albumin, Coagulation Factor Concentrates, Immunoglobulin, and Protease Inhibitors. The Coagulation Factor Concentrates is further studied across Factor IX, Factor VIII, Factor XIII, Fibrinogen Concentrates, Prothrombin Complex Concentrate, and Von Willebrand Factor. The Immunoglobulin is further studied across Intravenous Immunoglobulin and Subcutaneous Immunoglobulin.
  • Based on Application, market is studied across Critical Care, Hemato-Oncology, Hematology, Neurology, Pulmonology, and Rheumatology.
  • Based on End-User, market is studied across Academic & Research Institutes and Clinical Research Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Improving access to plasma-based therapies and high use of immunoglobulins in various therapeutic areas
      • 5.1.1.2. Government initiatives to increase plasma collection
      • 5.1.1.3. Growing prevalence of elderly people around the globe and the increasing number of blood collection facilities
    • 5.1.2. Restraints
      • 5.1.2.1. Presence of new pathogenic agents that resist the present viral inactivation treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous advancements in process development technology for improved formulations
      • 5.1.3.2. Exponential utilization in new clinical trials and growing R&D activities in plasma treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising use of plasma fractionation for immunoglobulins purification
    • 5.2.2. Application: Proliferating use to treat hematological disorders
    • 5.2.3. End-User: Extensive use of plasma fractionation in clinical research laboratories to ensure the safety and efficacy of plasma-derived products
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Plasma Fractionation Market, by Product

  • 6.1. Introduction
  • 6.2. Albumin
  • 6.3. Coagulation Factor Concentrates
    • 6.3.1. Factor IX
    • 6.3.2. Factor VIII
    • 6.3.3. Factor XIII
    • 6.3.4. Fibrinogen Concentrates
    • 6.3.5. Prothrombin Complex Concentrate
    • 6.3.6. Von Willebrand Factor
  • 6.4. Immunoglobulin
    • 6.4.1. Intravenous Immunoglobulin
    • 6.4.2. Subcutaneous Immunoglobulin
  • 6.5. Protease Inhibitors

7. Plasma Fractionation Market, by Application

  • 7.1. Introduction
  • 7.2. Critical Care
  • 7.3. Hemato-Oncology
  • 7.4. Hematology
  • 7.5. Neurology
  • 7.6. Pulmonology
  • 7.7. Rheumatology

8. Plasma Fractionation Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Clinical Research Laboratories

9. Americas Plasma Fractionation Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Plasma Fractionation Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Plasma Fractionation Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Grifols Egypt delivers first plasma medicines made from Egyptian plasma donations
    • 12.3.2. CSL's USD470 Million Plasma Fractionation Facility Opens in Marburg, Germany
    • 12.3.3. Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
    • 12.3.4. Kedrion presented at plasma fractionation workshop in Saudi Arabia
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3M Company
  • 2. ADMA Biologics, Inc.
  • 3. Bharat Serums and Vaccines Limited
  • 4. Bio Products Laboratory Ltd.
  • 5. Biotest AG by Grifols, S.A.
  • 6. China Biologic Products, Inc.
  • 7. CSL Limited
  • 8. Emergent BioSolutions Inc.
  • 9. Fusion Health Care Pvt. Ltd.
  • 10. GC Biopharma corp.
  • 11. Grifols, S.A.
  • 12. HEINKEL Process Technology GmbH
  • 13. Hemarus Therapeutics Ltd
  • 14. Intas Pharmaceuticals Ltd.
  • 15. Kamada Ltd.
  • 16. Kedrion S.p.A.
  • 17. LFB SA
  • 18. Merck KGaA
  • 19. Octapharma AG
  • 20. PlasmaGen BioSciences Pvt. Ltd.
  • 21. Prothya Biosolutions B.V.
  • 22. Sanquin
  • 23. Shanghai Raas Blood Products Co. Ltd
  • 24. SK Plasma Co.,Ltd.
  • 25. STERIS plc
  • 26. Takeda Pharmaceutical Company Ltd

LIST OF FIGURES

  • FIGURE 1. PLASMA FRACTIONATION MARKET RESEARCH PROCESS
  • FIGURE 2. PLASMA FRACTIONATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PLASMA FRACTIONATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PLASMA FRACTIONATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PLASMA FRACTIONATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PLASMA FRACTIONATION MARKET DYNAMICS
  • TABLE 7. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FACTOR XIII, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FIBRINOGEN CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY VON WILLEBRAND FACTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRITICAL CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATO-ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. PLASMA FRACTIONATION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. PLASMA FRACTIONATION MARKET, FPNV POSITIONING MATRIX, 2023